Diabetes Digital Therapeutic (dtx)
We are benchmarking companies in the diabetes dtx space and would like some basic understanding and below information specifically for ihealth, oculocare, better therapeutics and retinarisk.
1) target customer, customer base size and geographies available in
2) business model
3) pricing model and revenue streams
4) data flow and data collaboration partner
5) product features, value proposition and differentiator.
+13 Other ResponsesMedical Devices
Hi zintro expert,
the zintro blog needs you! we are looking for expert opinions on the news mentioned below and would like to include your point of view. We realize your time is valuable, so here is a brief summary of what we are looking for:
⢠a brief answer to the prompt â about 1-2 paragraphs â including your full name
⢠participation is voluntary â no payment will be involved
⢠if chosen, youâll be named in the post and weâll include a link to your zintro profile which will generate more visitors for you
wondering what the post would look like? Here is a sample: http://blog.Zintro.Com/2012/01/16/keystone-xl-pipeline-pros-and-cons/
medical devices
research from scientists at the stanford university school of medicine could make it possible for young people with type-1 diabetes to sleep safely. Many diabetics who are able to recognize warning signs of low blood-sugar levels during the day run into problems at night when they are asleep. A special glucose sensor was able to predict and even prevent dangerously low overnight blood sugars in adolescents and adults with type-1 diabetes. What are your thoughts about the study and device, highlighted in diabetes care? Details of the study are available at http://care.Diabetesjournals.Org/content/37/5/1204.
Getting your name and expert opinion published on our blog is a great marketing opportunity. If interested, please send a response to the prompt via znotes within 1-2 days. Donât forget to include your full name.
If you have any questions, please let us know.
Thank you!
the zintro blog team
+4 Other Responses
